NurExone Biologic Company Description

NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries.

It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis caused by spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat traumatic brain injuries and other neurological conditions.

Its technology includes ExoPTEN for the treatment of acute spinal cord injury and glaucoma; and Exosomes as a drug delivery system for regeneration and healing of specific tissues.

The company was founded in 2020 and is based in Toronto, Canada.

NurExone Biologic Inc.

Country	Canada
Founded	2020
Industry	Biotechnology
Sector	Healthcare
CEO	Lior Shaltiel

Contact Details

Address: 1 Adelaide Street East Toronto, Ontario M5C 2V9 Canada
Website	nurexone.com

Stock Details

Ticker Symbol	NRX
Exchange	TSX Venture Exchange
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Jacob Licht	Chief Executive Officer of Exo-Top Inc. and Vice President of Corporate Development at NurExone
Dr. Lior Shaltiel Ph.D.	Chief Executive Officer and Director
Yoram Drucker	Co-Founder, Vice President of Strategic Development and Chairman
Eran Ovadya M.B.A.	Chief Financial Officer, Financial Director and Secretary
Gabriel Eldor	Co-Founder and Business Development Manager
Dr. Shulamit Levenberg Ph.D.	Co-Founder and Member of Scientific Advisory Board
Dr. Daniel Offen Ph.D.	Co-Founder
Dr. Tali Kizhner Ph.D.	Director of Research and Development
Prof. Nahshon Knoller M.D.	Head of the neurosurgery department at Shiba and Member of Scientific Advisory Board
Dr. Ina Sarel Ph.D.	Head of CMC, Quality and Regulation